LAS VEGAS — A drug-eluting stent benefited patients with lesions in the superficial femoral artery at 2 years, according to findings presented at VIVA 15.
Hiroyoshi Yokoi, MD, presented 2-year results from a postmarket surveillance study conducted in Japan of 907 patients (mean age, 74 years; 70% men) with 1,075 lesions treated with a DES (Zilver PTX, Cook Medical).
No commercial support for this activity.
This activity is supported by an educational grant from Salix, A Dvision of Valeant Pharmaceuticals North America, LLC.
New technologies advance treatment options for patients with arrhythmia disorders, HF
A look at ezetimibe and the IMPROVE-IT trial
PCSK9 inhibitors change treatment approach for dyslipidemia
This feature offers timely executive summaries of the most relevant journals in cardiology.
Snapshot summaries of recent study results in cardiology.
Your central portal for information presented at ACC 2015.
Your resource for news and videos from SCAI 2014.
This exclusive Healio resource provides you a comprehensive window into what your colleagues and key opinion leaders are saying about current and future drugs and devices and their impact on patient outcomes.
Related story »
View past polls »
Search Healio's robust listing of national and international medical meetings.
©2015 All Rights Reserved.